vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and First Bancorp, Inc (FNLC). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $13.8M, roughly 1.9× FENNEC PHARMACEUTICALS INC.). First Bancorp, Inc runs the higher net margin — 39.4% vs -34.7%, a 74.1% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 17.5%). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
FENC vs FNLC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $25.8M |
| Net Profit | $-4.8M | $10.2M |
| Gross Margin | — | — |
| Operating Margin | -18.5% | 48.1% |
| Net Margin | -34.7% | 39.4% |
| Revenue YoY | 73.8% | 17.5% |
| Net Profit YoY | -141.1% | 39.7% |
| EPS (diluted) | $-0.17 | $0.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $25.8M | ||
| Q3 25 | $12.5M | $24.5M | ||
| Q2 25 | $9.7M | $22.5M | ||
| Q1 25 | $8.8M | $21.8M | ||
| Q4 24 | $7.9M | $22.0M | ||
| Q3 24 | $7.0M | $20.5M | ||
| Q2 24 | $7.3M | $19.2M | ||
| Q1 24 | $25.4M | $18.5M |
| Q4 25 | $-4.8M | $10.2M | ||
| Q3 25 | $-638.0K | $9.1M | ||
| Q2 25 | $-3.2M | $8.1M | ||
| Q1 25 | $-1.2M | $7.1M | ||
| Q4 24 | $-2.0M | $7.3M | ||
| Q3 24 | $-5.7M | $7.6M | ||
| Q2 24 | $-5.6M | $6.2M | ||
| Q1 24 | $12.8M | $6.0M |
| Q4 25 | -18.5% | 48.1% | ||
| Q3 25 | -1.5% | 45.2% | ||
| Q2 25 | -28.3% | 43.7% | ||
| Q1 25 | -9.2% | 39.3% | ||
| Q4 24 | -11.8% | 39.5% | ||
| Q3 24 | -74.6% | 44.6% | ||
| Q2 24 | -69.4% | 38.8% | ||
| Q1 24 | 54.2% | 39.3% |
| Q4 25 | -34.7% | 39.4% | ||
| Q3 25 | -5.1% | 37.0% | ||
| Q2 25 | -32.7% | 35.8% | ||
| Q1 25 | -13.3% | 32.5% | ||
| Q4 24 | -25.0% | 33.1% | ||
| Q3 24 | -82.2% | 36.9% | ||
| Q2 24 | -76.5% | 32.1% | ||
| Q1 24 | 50.6% | 32.5% |
| Q4 25 | $-0.17 | $0.91 | ||
| Q3 25 | $-0.02 | $0.81 | ||
| Q2 25 | $-0.11 | $0.72 | ||
| Q1 25 | $-0.04 | $0.63 | ||
| Q4 24 | $-0.02 | $0.66 | ||
| Q3 24 | $-0.21 | $0.68 | ||
| Q2 24 | $-0.20 | $0.55 | ||
| Q1 24 | $0.41 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | — |
| Total DebtLower is stronger | — | $95.5M |
| Stockholders' EquityBook value | $35.5M | $283.1M |
| Total Assets | $70.6M | $3.2B |
| Debt / EquityLower = less leverage | — | 0.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | — | ||
| Q3 25 | $21.9M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $22.7M | — | ||
| Q4 24 | $26.6M | — | ||
| Q3 24 | $40.3M | — | ||
| Q2 24 | $43.1M | — | ||
| Q1 24 | $51.2M | — |
| Q4 25 | — | $95.5M | ||
| Q3 25 | $19.4M | $95.5M | ||
| Q2 25 | $19.4M | $95.0M | ||
| Q1 25 | $19.4M | $70.0M | ||
| Q4 24 | $19.3M | $95.0M | ||
| Q3 24 | $32.1M | $95.0M | ||
| Q2 24 | $31.8M | $70.0M | ||
| Q1 24 | $31.3M | $70.0M |
| Q4 25 | $35.5M | $283.1M | ||
| Q3 25 | $-4.5M | $274.6M | ||
| Q2 25 | $-7.5M | $265.5M | ||
| Q1 25 | $-5.9M | $259.7M | ||
| Q4 24 | $-5.9M | $252.5M | ||
| Q3 24 | $-5.2M | $256.8M | ||
| Q2 24 | $-1.4M | $244.7M | ||
| Q1 24 | $3.0M | $242.6M |
| Q4 25 | $70.6M | $3.2B | ||
| Q3 25 | $49.3M | $3.2B | ||
| Q2 25 | $44.9M | $3.2B | ||
| Q1 25 | $46.4M | $3.2B | ||
| Q4 24 | $44.9M | $3.2B | ||
| Q3 24 | $58.9M | $3.1B | ||
| Q2 24 | $63.2M | $3.1B | ||
| Q1 24 | $69.2M | $3.0B |
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | 10.40× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $37.8M |
| Free Cash FlowOCF − Capex | — | $34.6M |
| FCF MarginFCF / Revenue | — | 133.9% |
| Capex IntensityCapex / Revenue | — | 12.5% |
| Cash ConversionOCF / Net Profit | — | 3.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $37.8M | ||
| Q3 25 | $1.5M | $12.9M | ||
| Q2 25 | $-3.7M | $7.4M | ||
| Q1 25 | $-4.3M | $2.2M | ||
| Q4 24 | $-1.5M | $26.0M | ||
| Q3 24 | $-2.2M | $9.8M | ||
| Q2 24 | $-8.4M | $6.4M | ||
| Q1 24 | $39.0M | $-1.5M |
| Q4 25 | — | $34.6M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | — | $7.2M | ||
| Q1 25 | — | $828.0K | ||
| Q4 24 | — | $24.6M | ||
| Q3 24 | — | $9.6M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | 133.9% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 111.7% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | — | 32.9% | ||
| Q1 24 | — | -9.8% |
| Q4 25 | — | 12.5% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | 3.04× | -0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
